These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8447559)

  • 21. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD; Becker EE; LaBelle JL; Truitt RL
    J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models.
    Vourka-Karussis U; Ackerstein A; Pugatsch T; Slavin S
    Exp Hematol; 1999 Mar; 27(3):461-9. PubMed ID: 10089908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunodominant CD4+ T cell receptor Vbeta repertoires involved in graft-versus-host disease responses to minor histocompatibility antigens.
    Berger MA; Korngold R
    J Immunol; 1997 Jul; 159(1):77-85. PubMed ID: 9200441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Studies of immunologic tolerance to host minor histocompatibility antigens following allogeneic bone marrow transplantation in mice.
    Perreault C; Allard A; Brochu S; Poupart C; Fontaine P; Bélanger R; Gyger M
    Bone Marrow Transplant; 1990 Aug; 6(2):127-35. PubMed ID: 2145050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repertoire analysis of CD8+ T cell responses to minor histocompatibility antigens involved in graft-versus-host disease.
    Friedman TM; Gilbert M; Briggs C; Korngold R
    J Immunol; 1998 Jul; 161(1):41-8. PubMed ID: 9647205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation.
    Goulmy E; Schipper R; Pool J; Blokland E; Falkenburg JH; Vossen J; Gratwohl A; Vogelsang GB; van Houwelingen HC; van Rood JJ
    N Engl J Med; 1996 Feb; 334(5):281-5. PubMed ID: 8532022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Graft-versus-host disease impairs vaccine responses through decreased CD4+ and CD8+ T cell proliferation and increased perforin-mediated CD8+ T cell apoptosis.
    Capitini CM; Nasholm NM; Duncan BB; Guimond M; Fry TJ
    J Immunol; 2013 Feb; 190(3):1351-9. PubMed ID: 23275602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of graft-versus-host disease by double-negative regulatory T cells.
    Young KJ; DuTemple B; Phillips MJ; Zhang L
    J Immunol; 2003 Jul; 171(1):134-41. PubMed ID: 12816991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lethal GVHD across minor histocompatibility barriers: nature of the effector cells and role of the H-2 complex.
    Korngold R; Sprent J
    Immunol Rev; 1983; 71():5-29. PubMed ID: 6221991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunodominance in the graft-vs-host disease T cell response to minor histocompatibility antigens.
    Korngold R; Wettstein PJ
    J Immunol; 1990 Dec; 145(12):4079-88. PubMed ID: 2258608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
    Drobyski WR; Majewski D; Ozker K; Hanson G
    J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunomonitoring of graft-versus-host minor histocompatibility antigen correlates with graft-versus-host disease and absence of relapse after graft.
    Laurin D; Hannani D; Pernollet M; Moine A; Plumas J; Bensa JC; Cahn JY; Garban F
    Transfusion; 2010 Feb; 50(2):418-28. PubMed ID: 19843288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strain dependence of interleukin-2-induced graft-versus-host disease protection: evidence that interleukin-2 inhibits selected CD4 functions.
    Sykes M; Harty MW; Pearson DA
    J Immunother Emphasis Tumor Immunol; 1994 Jan; 15(1):11-21. PubMed ID: 8110726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease.
    Mutis T; Gillespie G; Schrama E; Falkenburg JH; Moss P; Goulmy E
    Nat Med; 1999 Jul; 5(7):839-42. PubMed ID: 10395333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative effects of various T cell subtypes on GVHD in a murine model for MHC-matched unrelated donor transplant.
    OKunewick JP; Kociban DL; Buffo MJ
    Bone Marrow Transplant; 1990 Mar; 5(3):145-52. PubMed ID: 1691938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of purified CD8+ T cells in graft-versus-leukemia activity and engraftment after allogeneic bone marrow transplantation.
    Palathumpat V; Dejbakhsh-Jones S; Strober S
    Transplantation; 1995 Aug; 60(4):355-61. PubMed ID: 7652765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T cell immunity and graft-versus-host disease (GVHD).
    Ichiki Y; Bowlus CL; Shimoda S; Ishibashi H; Vierling JM; Gershwin ME
    Autoimmun Rev; 2006 Jan; 5(1):1-9. PubMed ID: 16338205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
    Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
    J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclosporine-induced syngeneic graft-vs-host disease: prevention of autoaggression by treatment with monoclonal antibodies to T lymphocyte cell surface determinants and to MHC class II antigens.
    Hess AD; Horwitz LR; Laulis MK; Fuchs E
    Clin Immunol Immunopathol; 1993 Dec; 69(3):341-50. PubMed ID: 7694818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.